CD47 and colorectal carcinoma: The ELEVATE CRC study evaluated magrolimab (CD47 inhibitor) plus bevacizumab-5-fluorouracil, irinotecan and leucovorin (FOLFIRI) in mCRC.<h4>Patients and methods</h4>This open-label, phase II study enrolled eligible patients with previously treated advanced inoperable mCRC.